HC-7366

Clinical trials for HC-7366 explained in plain language.

Never miss a new study

Get alerted when new HC-7366 trials appear

Sign up with your email to follow new studies for HC-7366, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for Tough-to-Treat kidney cancer? early trial tests novel drug combo

Disease control Not yet recruiting

This early-stage study aims to see if a new drug called HC-7366, when combined with standard immunotherapy drugs (nivolumab with or without ipilimumab), can help control advanced clear cell kidney cancer. It will enroll about 35 adults to test the safety of these combinations and…

Matched conditions: HC-7366

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 23, 2026 15:16 UTC

HC-7366

Get alerted when new HC-7366 trials appear

New hope for Tough-to-Treat kidney cancer? early trial tests novel drug combo